Search

Asymptomatic patients Intervention is recommended in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <50%) without another cause (class I, B). Interventi

FIND OUT MORE: CLINICAL DATA © Abbott 2024. All rights reserved. 9-EH-5-14528-01 05-2024 REV A

STUDY DEMONSTRATING CASE FOR EARLY DEVICE INTERVENTION LEARN MORE INCREASED EXPERIENCE LEADS TO A MODIFIED PDA CLOSURE TECHNIQUE LEARN MORE FIND OUT MORE: Amplatzer Piccolo™ Clinical Trial

PATENT DUCTUS ARTERIOSUS FIND OUT MORE: PATIENTS WHO BENEFIT © Abbott 2024. All rights reserved. 9-EH-5-14528-01 05-2024 REV A

Watch R. S. von Bardeleben & E. Donal giving their perspective. R. S. von Bardeleben E. Donal RESHAPE-HF2 A second randomised clinical trial for MitraClip™ Transcatheter Edge-to-Edge Repai

CONTACT US Contact Us With CONNEXT by Advanced Heart Therapies, Abbott is committed to providing clinicians with best-in-class tailored educational content and sharing best practices and opportuni

EVERY DETAIL IS DESIGNED FOR SUCCESSFUL PVL CLOSURE The Amplatzer™ Valvular Plug III has been specially designed to offer patients an effective solution to PVL. This oblong, self-expanding device i

© Abbott 2023. All rights reserved. 9-EH-5-14389-01 07-2023

Rama-Merchan J, Arribas-Jimenez A, et al. Prevalence and severity of paravalvular regurgitation in the Artificial Valve Endocarditis Reduction Trial (AVERT) echocardiography study. Rev Esp Cardiol.

AMPLATZER™ MUSCULAR VSD OCCLUDER DEMONSTRATED CLOSURE SUCCESS IN PATIENTS WITH VSD The Amplatzer™ Muscular VSD Occluder was evaluated in a prospective, non-randomized, multi-center clinical study